Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Jimenez

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
JTO Clinical and Research Reports|September 30, 2021
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung TrialJordi Remon, Benjamin Besse, Alexandra Leary, et al.
Plos One|April 26, 2021
Validity and reliability of the Spanish version of the "Wijma Delivery Expectancy/Experience Questionnaire" (W-DEQ-B)Juan Roldán-Merino, Celia Maria Ortega-Cejas, Teresa Lluch-Canut, et al.
British Journal of Cancer|June 12, 2025
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signatureSolenn Barraud, Sophie Vacher, Camille Schiffler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyNicolas Penel, Binh Nguyen Bui, Jacques-Olivier Bay, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)Mario Campone, Thomas Bachelot, Isabelle Treilleux, et al.
European Journal of Heart Failure|August 17, 2025
Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESCGuillaume Baudry, Maria Generosa Crespo-Leiro, Clément Delmas, et al.
British Journal of Cancer|January 5, 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestaneHélène Vanacker, Isabelle Treilleux, Camille Schiffler, et al.
The Lancet. Oncology|February 11, 2014
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)Fabrice André, Thomas Bachelot, Frederic Commo, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|May 11, 2021
Development and validation of a laboratory-based risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19Salomon Martin, Sandra Fuentes, Catalina Sanchez, et al.
Cancer Research|March 9, 2021
Genomic Alterations in <i>PIK3CA</i>-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα InhibitorsYanyan Cai, Guotai Xu, Fan Wu, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
JTO Clinical and Research Reports|September 30, 2021
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung TrialJordi Remon, Benjamin Besse, Alexandra Leary, et al.
Plos One|April 26, 2021
Validity and reliability of the Spanish version of the "Wijma Delivery Expectancy/Experience Questionnaire" (W-DEQ-B)Juan Roldán-Merino, Celia Maria Ortega-Cejas, Teresa Lluch-Canut, et al.
British Journal of Cancer|June 12, 2025
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signatureSolenn Barraud, Sophie Vacher, Camille Schiffler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyNicolas Penel, Binh Nguyen Bui, Jacques-Olivier Bay, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)Mario Campone, Thomas Bachelot, Isabelle Treilleux, et al.
European Journal of Heart Failure|August 17, 2025
Identifying and overcoming barriers to referral in advanced heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESCGuillaume Baudry, Maria Generosa Crespo-Leiro, Clément Delmas, et al.
British Journal of Cancer|January 5, 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestaneHélène Vanacker, Isabelle Treilleux, Camille Schiffler, et al.
The Lancet. Oncology|February 11, 2014
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)Fabrice André, Thomas Bachelot, Frederic Commo, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|May 11, 2021
Development and validation of a laboratory-based risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19Salomon Martin, Sandra Fuentes, Catalina Sanchez, et al.
Cancer Research|March 9, 2021
Genomic Alterations in <i>PIK3CA</i>-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα InhibitorsYanyan Cai, Guotai Xu, Fan Wu, et al.
Pageof 8